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Abstract
Background: Angiogenesis is one of the mechanisms most critical to the postoperative recurrence and
metastasis of hepatocellular carcinoma (HCC). Thus, finding the molecular markers associated with
angiogenesis may help identify patients at increased risk for recurrence and metastasis of HCC. This study
was designed to investigate whether CD105 or CD34 could serve as a valid prognostic marker in patients
with HCC by determining if there is a correlation between CD105 or CD34 expression and postoperative
recurrence or metastasis.
Methods: Immunohistochemical staining for the CD105, CD34 and vascular endothelial growth factor
(VEGF) antibodies was performed in 113 HCC tissue specimens containing paracarcinomatous tissue and
in 14 normal liver tissue specimens. The quantitation of microvessels identified by anti-CD105 and anti-
CD34 monoclonal antibodies and the semiquantitation of VEGF expression identified by anti-VEGF
monoclonal antibody were analyzed in conjunction with the clinicopathological characteristics of the HCC
and any available follow-up information about the patients from whom the specimens were obtained.
Results:  CD105 was not expressed in the vascular endothelial cells of any normal liver tissue or
paracarcinomatous liver tissue but was expressed in the vascular endothelial cells of all HCC tissue. In
contrast, CD34 was expressed in the vascular endothelial cells of normal liver tissue, paracarcinomatous
tissue, and HCC tissue in the following proportions of specimens: 86.7%, 93.8%, and 100%, respectively.
The microvascular densities (MVDs) of HCC determined by using an anti-CD105 mAb (CD105-MVD) and
an anti-CD34 mAb (CD34-MVD), were 71.7 ± 8.3 (SD) and 106.3 ± 10.4 (SD), respectively. There was a
significant correlation between CD105-MVD and CD34-MVD (r = 0.248, P = 0.021). Although CD34-MVD
was significantly correlated with VEGF expression (r = 0.243, P = 0.024), CD105-MVD was more closely
correlated (r = 0.300, P= 0.005). The correlation between microscopic venous invasion and CD105-MVD,
but not CD34-MVD, was also statistically significant (r = 0.254, P = 0.018). Univariate analysis showed that
CD105-MVD was significantly correlated with the 2-year overall survival rate (P = 0.014); CD34-MVD was
not (P = 0.601). Multivariate analysis confirmed that CD105-MVD was an independent prognostic factor
and that CD34-MVD was not.
Conclusion: The anti-CD105 mAb is an ideal instrument to quantify new microvessels in HCC as
compared with anti-CD34 mAb. CD105-MVD as compared with CD34-MVD is relevant a significant and
independent prognostic indicator for recurrence and metastasis in HCC patients.
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Background
Hepatocellular carcinoma (HCC) is one of the most com-
mon cancers worldwide, especially in China, where it has
been ranked as the second leading cancer killer since the
1990s [1]. Although some advances have occurred in the
diagnosis and treatment of HCC, the long-term outcome
for affected patients is still very poor: the 5-year recurrence
rate of HCC is as high as 50% to 60% [2]. Therefore, iden-
tifying the molecular markers that correlate with the recur-
rence or metastasis of HCC may help improve the
outcome in these patients.
Angiogenesis is one of the mechanisms most critical to the
postoperative recurrence and metastasis of HCC [3-5].
Thus, finding the molecular markers associated with ang-
iogenesis may help identify patients at increased risk for
recurrence and metastasis of HCC, and thus those who
require more aggressive therapy and closer surveillance.
To date, however, no such marker has been definitively
identified. One potential marker is the degree of neovas-
cularization (ie, the microvascular density [MVD]). Sev-
eral researchers have demonstrated that the MVD, as
evaluated by an anti-CD34 monoclonal antibody (mAb)
(CD34-MVD), was closely correlated with the prognosis
of HCC [6,7]. However, other investigators have not
found any such correlation [8,9]. These conflicting results
are most likely due to the different reactivities of the anti-
endothelial cell antibodies used to stain the intratumoral
microvessels [10].
For example, antibodies against pan-endothelial cells,
such as the anti-CD34 mAb, react with not only newly
formed vessels but also normal vessels trapped within
tumor tissues [11,12]. In contrast, the anti-CD105 mAb
preferentially reacts with the activated endothelial cells of
angiogenic tissues, including tumors, but weakly or not at
all with the endothelial cells of most normal tissues
[10,12-23]. Thus, the detection of CD105 is likely to be
useful not only for its prognostic value as a means to iden-
tify candidates for specific antiangiogenic therapy. In fact,
some investigators have already demonstrated that the
MVD of cells, determined with an anti-CD105 mAb
(CD105-MVD) but not with an anti-CD34 mAb, corre-
lates with prognosis in some other types of carcinoma,
such as breast, renal cell, and colorectal carcinoma [24-
29]. Thus, our study attempts to investigate a correlation
between CD105-MVD and the postoperative recurrence
or metastasis of HCC.
Methods
Patients and specimens
The study protocol was approved by the Ethics Committee
of the Central South University. Tumor tissue specimens
from 113 patients with HCC who underwent complete
tumor resection without any preoperative therapy in
Xiang Ya Hospital in China from 1994 to 1997 were ret-
rospectively reviewed. All tumors were pathologically
confirmed to be HCC containing paracarcinomatous tis-
sues. Paracarcinomatous tissue is taken from non-cancer-
ous tissue 1 cm away from the tumor margin. Normal
liver tissue excised near the HCC in 14 patients was also
reviewed. The age of patients ranged from 18 to 73 years,
with a mean age of 44.4 years (± 11.0 years [SD]). Of the
113 patients, 78 were men and 35 were women.
Follow-up information about the postoperative clinical
course of patients was available from outpatient medical
records, telephone calls, or letters. Follow-up was success-
fully completed in 91.2% of the patients for a median of
2 years (range, 3 months-7 years). Intraoperative therapy
was not used in any patient. Overall survival time was cal-
culated as the period from surgery until death.
All tumor samples had been fixed in 10% formalin and
then embedded in paraffin. Serial 4-µm sections obtained
from each specimen were subjected not only to routine
hematoxylin and eosin staining to determine their clinico-
pathological features such as venous invasion, capsule for-
mation, Edmondson's grade, cirrhotic nodule but also to
immunohistochemical staining to detect antigens to
CD105, CD34, and vascular endothelial growth factor
(VEGF), a known marker of angiogenesis.
Microvessel counting and VEGF scoring
Immunohistochemical staining for CD34, CD105, and
VEGF was performed using a sensitive streptavidin-bioti-
nylated horseradish-peroxidase complex method. The
antibodies used in our study were purchased as following:
mAb to CD105(clone SN6h, NEOMARKERS), mAb to
CD34(clone QBEnd/10, NEOMARKERS), or mAb to
VEGF(clone JH121, NEOMARKERS)
All of the procedures were performed according to the
manufacturer's protocol. Briefly, deparaffinized and rehy-
drated tissue sections were incubated in 3% hydrogen per-
oxide diluted with methanol for 30 minutes to block the
endogenous peroxidase activity. Antigen retrieval was per-
formed by first pretreating sections in a microwave oven
or incubating them in 0.1% trypsin for 10 minutes at
37.0°C, after which nonspecific immunoreactivity was
blocked by incubating the tissue in normal goat serum at
room temperature for 5 minutes before application of the
mAb to CD105(clone SN6h, NEOMARKERS), mAb to
CD34(clone QBEnd/10, NEOMARKERS), or mAb to
VEGF(clone JH121, NEOMARKERS), which were diluted
with phosphate-buffered saline (PBS; 0.01 M, pH7.2) at a
ratio of 1:100 for 1 h at 37°C.
The sections were then washed in PBS and sequentially
incubated in biotinylated goat anti-mouse immunoglob-BMC Cancer 2006, 6:110 http://www.biomedcentral.com/1471-2407/6/110
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ulin G and a streptavidin-biotinylated horseradish- perox-
idase complex, according to the manufacturer's
instructions (ABC kit; Boster Ltd, Wuhan, China). The
staining was performed by immersing slides in 0.05% 3,3'
-diaminobenzidine tetrahydrochloride. All tissue sections
were counterstained with hematoxylin, dehydrated, and
mounted. PBS, substituted for the primary antibody, was
used as a negative control.
The immunostained sections are scanned at low magnifi-
cation (×40), and three tumor area with the highest den-
sity of distinctly highlighted microvessels ("hot spot")
within each section were selected for quantitation of ang-
iogenesis. All brown-stained endothelial cell or endothe-
lial cell cluster, which was clearly separate from
connective tissue elements, was considered a microvessel.
Counting was performed at a high magnification(× 200).
The mean counts for each specimen were recorded as the
CD34-MVD or the CD105-MVD [30]. VEGF expression
was evaluated by the scoring method reported by Shimizu
[31]. The immunohistochemical results for VEGF are clas-
sified as follows: -, no staining; +, weak staining; ++,
strong staining. Microvessel counting and VEGF scoring
were performed simultaneously by two independent
investigators without any knowledge of the characteristics
of the patients from whom the specimens came.
Statistical analysis
MVD values were compared between groups categorized
by their various clinicopathological features by using the
Student's t test. The postoperative survival rate was ana-
lyzed by the Kaplan-Meier method, and the differences
were assessed by the log-rank test. A multivariate analysis
of the possible prognostic markers was performed using
Cox's regression model. Differences were considered sig-
nificant when P was less than 0.05. All statistical manipu-
lations were performed using the SPSS for Windows
system (version 10.0; SPSS Institute, Cary, NC).
Results
CD105 and CD34 expression
CD105 was not expressed in the vascular endothelial cells
of the 14 normal liver tissues and the paracarcinomatous
liver tissue in any of the 113specimens (Fig. 1A–C) but
was expressed in the vascular endothelial cells of HCC tis-
sue of all specimens. In contrast, CD34 was expressed in
the following proportions of specimens of the vascular
endothelial cells of normal liver tissue, paracarcinoma-
tous tissue, and HCC tissue: 86.7%, 93.8% and 100%,
respectively (Figure 1, D-F). The CD105-MVD and CD34-
MVD were 71.7 ± 8.3 (SD) and 106.3 ± 10.4 (SD), respec-
tively. There was a significant correlation between the
A, Positive staining for CD105 in HCC tissue (avidin-biotin-peroxidase complex, original magnification × 200) Figure 1
A, Positive staining for CD105 in HCC tissue (avidin-biotin-peroxidase complex, original magnification × 200). B, Negative 
staining for CD105 in paracarcinomatous liver tissue (avidin-biotin-peroxidase complex, original magnification × 200). C, Nega-
tive staining for CD105 in normal liver tissue (avidin-biotin-peroxidase complex, original magnification × 200). D, Positive stain-
ing for CD34 in HCC tissue (avidin-biotin-peroxidase complex, original magnification × 200). E, Positive staining for CD34 in 
paracarcinomatous liver tissue (avidin-biotin-peroxidase complex, original magnification × 200). F, Positive staining for CD34 in 
normal liver tissue (avidin-biotin-peroxidase complex, original magnification × 200).BMC Cancer 2006, 6:110 http://www.biomedcentral.com/1471-2407/6/110
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CD105-MVD and the CD34-MVD (r = 0.248, P = 0.021;
Fig. 2).
MVD and VEGF expression
The CD105-MVD and CD34-MVD markedly increased
with enhanced VEGF expression (P = 0.005 and P = 0.024,
respectively) (Fig.3), indicating that both are markers of
the degree of angiogenesis.
MVD and clinicopathological features
The correlation between CD105-MVD and microscopic
venous invasion was significant (r = 0.254, P = 0.018). We
did not, however, find any significant correlation between
CD105-MVD and liver cirrhosis, tumor diameter, capsule
formation, Edmondson's grade, or preoperative α-feto-
protein concentration (Table 1). There was also no signif-
icant correlation between CD34-MVD and any of these
clinicopathological features. Thus, CD105 appears to be
both specific and sensitive as a marker of angiogenesis.
MVD and postoperative prognosis
The 1-year, 2-year, and 3-year overall survival rates of all
the HCC patients in our study were 65.1%, 30.1%, and
5.8%, respectively. The 2-year survival rate of HCC
patients with a lower CD105-MVD (< 56, the median
value) was 47.1%, which was significantly higher than the
13.5% rate of HCC patients with a higher CD105-MVD (P
= 0.014; Fig. 4A). Although the 2-year survival rate
(33.3%) of HCC patients with a lower CD34-MVD (<
94)) was also higher than that of HCC patients with a
higher CD34-MVD (26.9%), the difference was not signif-
icant (P = 0.601; Fig. 4B).
Multivariate analysis of CD105-MVD as a predictive factor
Multivariate analysis showed that a higher CD105-MVD
was a significant (P = 0.024) and independent factor pre-
dicting a poor prognosis (Table 2). When the CD34-MVD
was used in the regression model, however, it failed to
show a significant prognostic value (P = 0.072).
Discussion
The high incidence of postoperative recurrence and metas-
tasis has been the major obstacle to further improving the
overall survival rate of patients with HCC. Recently, much
attention has been paid to the association between angio-
genesis and postoperative recurrence or metastasis. Angio-
genesis, the formation of new blood vessels from
preexisting ones, is essential for any malignant tumor,
A, correlation between VEGF expression and CD34-MVD Figure 3
A, correlation between VEGF expression and CD34-MVD. B, 
correlation between VEGF expression and CD105-MVD.
Correlation between CD34-MVD and CD105-MVD Figure 2
Correlation between CD34-MVD and CD105-MVD.BMC Cancer 2006, 6:110 http://www.biomedcentral.com/1471-2407/6/110
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including HCC, to grow and metastasize; in fact, solid
tumors cannot grow beyond 1 to 2 mm in diameter in the
absence of angiogenesis. Therefore, the ability to quanti-
tatively distinguish between tumor neovascularization
and pre-existing vessels is important in the assessment of
tumor angiogenesis. The degree of neovascularization, or
MVD, is now generally identified by immunohistochemi-
cal staining of endothelial cells with the so-called pan-
endothelial cell markers such as CD34, CD31, and von
Willebrand factor; however, anti-pan-endothelial anti-
bodies can react with not only newly formed vessels but
also normal vessels trapped within tumor tissues. Thus,
the MVD identified by anti-pan-endothelial antibodies is
not an ideal prognostic marker. It is necessary to find a
marker that specifically reacts with the endothelial cells of
angiogenic tissue and not with the endothelial cells of
most normal tissue.
Endoglin (CD105) is a proliferation-associated and
hypoxia-inducible glycoprotein abundantly expressed in
angiogenic endothelial cells [32,33]. It is a receptor for the
transforming growth factor β superfamily [34,35] and is
essential in angiogenesis [36]. Immunohistochemical
studies have shown that CD105 is strongly expressed in
blood vessels of tumor tissue. The intensity of staining for
CD105 is greater in blood vessel endothelia within neo-
plastic tissue than within normal tissues, indicating that
CD105 is a powerful marker of neovascularization in
solid malignancies. The MVD determined with the anti-
CD105 antibody has been established as an independent
prognostic indicator, with increased values correlating
with shorter survival times.
To test whether the anti-CD105 mAb reacts only with new
vessels in HCC tissues, we used immunohistochemical
staining to determine the CD105 expression in tumor
specimens from 113 patients with HCC and correlated
our findings with available follow-up information about
the patients. We found that the anti-CD105 mAb was an
ideal marker to distinguish between the microvessels of
tumor and normal tissues and that CD105-MVD was sig-
nificantly correlated with prognosis in patients with HCC.
In addition, our finding of the expression of CD34 in both
normal and tumor tissue indicated that it is not a reliable
marker for HCC.
When we studied the correlation between the expression
of MVD and VEGF, a known marker for angiogenesis, we
found that although CD34-MVD was significantly corre-
lated with VEGF expression (r = 0.243), CD105-MVD was
more closely correlated (r = 0.300). This finding further
showed that the anti-CD105 antibody is superior to the
anti-CD34 antibody in detecting angiogenesis in HCC.
However, because angiogenesis is influenced not only by
VEGF, to verify the view of CD105 as a marker, compara-
tive studies need to be performed to evaluate the correla-
tion of the CD34-MVD and the CD105-MVD with other
factors that influence angiogenesis.
When we analyzed MVD in conjunction with the clinico-
pathological characteristics of the HCC tumors, we found
that the CD105-MVD, but not the CD34-MVD, was
strongly correlated with the presence of microscopic
venous invasion; microscopic venous invasion has been
shown by other studies to be one of the most accurate
Table 1: Correlation between microvascular density and clinicopathological features of 113 tumors
Feature No. Microvascular density
CD105* P value CD34* P value
Venous invasion
No 52 57.04 ± 5.88 0.032 95.71 ± 5.50 0.392
Yes 61 84.19 ± 3.73 115.33 ± 4.39
Capsule formation
Negative 32 56.30 ± 2.39 0.114 90.51 ± 7.69 0.130
Positive 81 77.78 ± 1.88 112.54 ± 4.97
Edmondson's grade
I--II 41 63.96 ± 4.55 0.281 105.38 ± 6.17 0.970
III--IV 72 76.11 ± 8.63 106.82 ± 8.22
Cirrhotic nodule
≤3 mm 33 69.71 ± 7.60 0.822 99.04 ± 5.78 0.461
> 3 mm 80 72.52 ± 9.78 109.29 ± 8.77
Serum α-fetoprotein level
≤20 ng/ml 21 63.60 ± 7.90 0.384 102.92 ± 2.46 0.738
> 20 ng/ml 92 73.55 ± 9.11 107.07 ± 2.78
*Values are means ± SD.BMC Cancer 2006, 6:110 http://www.biomedcentral.com/1471-2407/6/110
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prognostic indicators of postoperative recurrence and
metastasis in HCC [38-40]. This correlation also suggested
that anti-CD105 antibodies react with new vessels in HCC
tissue more specifically than do anti-CD34 antibodies. We
found no significant correlation between CD105-MVD
and liver cirrhosis, tumor diameter, capsule formation,
Edmondson's grade, or preoperative α-fetoprotein con-
centration, although other investigators have [41-44].
This discrepancy suggests that our results, although sensi-
tive, are potentially not specific, and further studies will
need to be done to confirm the specificity we observed for
the marker.
Kaplan-Meier analysis showed that the CD105-MVD, but
not the CD34-MVD, was significantly correlated with the
2-year survival rate, and multivariate analysis showed that
CD105-MVD, but not CD34-MVCD, was a significant and
independent prognostic factor, which was consistent with
the results of retrospective studies of other tumors.
Another major benefit of our study is that it identified a
CD-105 as a potential target of therapy in HCC. Because
angiogenesis is essential for metastasis and recurrence,
destroying the tumor-associated microvasculature with-
out severely damaging normal tissues or causing major
adverse effects is an appropriate goal for biological ther-
apy. An appropriate proliferation-associated antigen
located on the endothelial cells of tumors could be an
ideal target for this antiangiogenic therapy and have neg-
ligible adverse effects [45-50]. As demonstrated in our
study, the anti-CD105mAb specifically reacted with the
neovascular endothelial cells of HCC only. Thus, CD105
may be useful not only for its prognostic ability but also
in the treatment of patients with HCC.
Conclusion
In summary, the anti-CD105 mAb proved to be an ideal
means to quantify new vessels in HCC, and CD105-MVD
was a significant and independent prognostic factor for
HCC. We would like to add the cautionary note that a pro-
portion of our patients who were alive despite a relapse
had a low MVD and, after a longer follow-up period,
might be expected to do poorly. Therefore, our findings
need to be confirmed in larger cohorts of patients with a
longer follow-up period.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Postoperative overall survival rate of patients with HCC Figure 4
Postoperative overall survival rate of patients with HCC. The 
comparison shown is according to the MVD determined with 
an anti-CD105 mAb A or an anti-CD34 mAb B.
Table 2: Multivariate analysis of prognostic factors in 
hepatocellular carcinoma
Factor β P value Exp(B)
Analysis A
Venous invasion 0.563 0.041 1.852
Capsule formation 0.035 0.241 0.923
Edmondson's grade 0.272 0.364 1.427
Cirrhotic nodule 0.195 0.148 1.327
Serum AFP 0.047 0.286 0.814
CD34-MVD 0.381 0.072 1.314
Analysis B
Venous invasion 0.371 0.047 1.536
Capsule formation 0.013 0.191 1.043
Edmondson's grade 0.254 0.305 1.094
Cirrhotic nodule 0.093 0.174 0.978
Serum AFP 0.011 0.197 1.146
CD105-MVD 0.740 0.024 2.270
Abbreviations: AFP, α-fetoprotein level; MVD. Microvascular density.BMC Cancer 2006, 6:110 http://www.biomedcentral.com/1471-2407/6/110
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